Prime Medicine, Inc.
No SEC Form 4 filings for $PRME in the last 30 days.
See all $PRME insider activity →Prime Medicine (PRME) is analyzed for its thin float and heavy short interest, with a focus on institutional market maker activity. The stock experienced a post-IPO markdown, a capitulation floor at $1.11, and a July 2025 volume anomaly due to a $125.4M public offering. The company's financing structure and market maker interventions are examined for their impact on the stock's price.
Citizens maintained a Market Outperform rating and $7.00 price target for Prime Medicine (NASDAQ:PRME) after its first patient dosing in a Wilson disease trial. The company's market cap is $571M, with a current ratio of 3.05. Analysts highlight Prime Medicine's clinical-stage transition and gene-editing advancements, including FDA clearance for PM647 and a favorable arbitration outcome with Beam Therapeutics.
Prime Medicine Inc. (NASDAQ:PRME) dosed the first patient in a Phase 1/2 trial for PM577a, a gene therapy for Wilson disease. The trial targets the H1069Q mutation, the most common in North America and Europe. The FDA granted Rare Pediatric Disease designation to PM577, which may qualify for a Priority Review Voucher. Initial data is expected in 2027.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PRME (Prime Medicine, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PRME coverage spans financial news, technology and earnings.
The piece frames PRME’s technical breakout risk as structurally capped by newly issued equity supply, even as clinical dosing news drives short-term momentum.
Analyst upgrade with a higher price target may support upside pressure.
First-in-human dosing may lift sentiment and drive short-term buying pressure.
Positive regulatory milestone likely to boost near‑term demand and support higher valuation.
Sharp sell‑off due to heightened competitive uncertainty.
AlphAI scores every news story that mentions PRME with an AI model for sentiment and relevance, and aggregates insider trades from Prime Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Prime Medicine (PRME) is analyzed for its thin float and heavy short interest, with a focus on institutional market maker activity. The stock experienced a post-IPO markdown, a capitulation floor at $1.11, and a July 2025 volume anomaly due to a $125.4M public offering. The company's financing structure and market maker interventions are examined for their impact on the stock's price.
7 min readCitizens maintained a Market Outperform rating and $7.00 price target for Prime Medicine (NASDAQ:PRME) after its first patient dosing in a Wilson disease trial. The company's market cap is $571M, with a current ratio of 3.05. Analysts highlight Prime Medicine's clinical-stage transition and gene-editing advancements, including FDA clearance for PM647 and a favorable arbitration outcome with Beam Therapeutics.
1 min readPrime Medicine Inc. (NASDAQ:PRME) dosed the first patient in a Phase 1/2 trial for PM577a, a gene therapy for Wilson disease. The trial targets the H1069Q mutation, the most common in North America and Europe. The FDA granted Rare Pediatric Disease designation to PM577, which may qualify for a Priority Review Voucher. Initial data is expected in 2027.
2 min readPrime Medicine Inc (PRME) shares rose 12% after the FDA cleared its Investigational New Drug application for PM647, a gene therapy for Alpha-1 Antitrypsin Deficiency. The company plans a global Phase 1/2 clinical trial. This is Prime Medicine's second regulatory milestone in recent months.
2 min readGene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.
2 min readPrime Medicine (PRME) reported a Q2 2026 net loss of $42.1M, narrower than the prior year. R&D and G&A expenses decreased. The company advanced PM577a and PM647 toward clinical trials, with FDA clearances and data expected in 2027. PM359 received RMAT designation, with a potential BLA filing in 2027. PRME has $108.8M in cash, expected to last into 2027.
2 min readTD Cowen reiterated a Buy on Prime Medicine (NASDAQ:PRME) after an arbitration win against Beam Therapeutics. A tribunal ruled PM647 is within Prime’s field under a 2019 collaboration agreement and Prime owes no monetary damages. Prime plans an IND/CTA filing for PM647 in Q3 2026, with initial data in 2027. H.C. Wainwright set an $8 target; Citizens set $6.
6 min readPrime Medicine, Inc. (PRME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates -- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initia
5 min readPrime Medicine (NASDAQ:PRME) said a tribunal issued a positive, binding resolution in its arbitration with Beam Therapeutics over a 2019 Collaboration and License Agreement. The tribunal found PM647 is within the agreement’s “Field,” so Prime Medicine did not breach and owes no monetary damages. PM647 uses Prime Medicine’s universal liver lipid nanoparticle to edit the SERPINA1 E342K mutation in AATD.
3 min readPrime Medicine said it won a dispute with Beam Therapeutics over gene-editing technology rights related to AATD. Prime expects to start an AATD clinical trial this quarter, and its stock rose about 11% while Beam fell about 2%. Beam said it disagrees and may pursue further action, according to company statements.
7 min read
